Author and year | Mean tumor volume in cubic centimeter | Treatment modality | Dose/fraction | Median follow-up | Overall survival | Clinical outcome | Radiological outcome | Toxicities |
---|---|---|---|---|---|---|---|---|
Shin, 2009 [15] | 1.52 | LINAC | 14 Gy (10–16 Gy) / 1 fraction | 10 months | 8 (2–19) months | Improvement: 80%, Stable: 10%, Worse: 10% | Complete: 22%, Partial: 33%, Stable: 33%, Progression: 11% | None |
Parikh, 2009 [9] | NA | CK | 15 Gy/3 fractions | 26 months | 9,8 months | Improvement | Stable | None |
Dewas, 2011 [10] | NA | CK | 20 Gy / 4 fractions | 11 months | NR | Stable | Stable | None |
Lieberson, 2012 [11] | NA | CK | 27 Gy / 3 fractions | 3 months | 15 months | Stable | Complete | None |
Veeravagu, 2012 [16] | 1.17 | CK | 21 Gy (14–27 Gy) / 3 fractions (1–5) | NR | 2 months | Improvement: 11%, Stable: 44%, NA: 55% | Partial: 22%, Stable: 22%, NA: 78% | None |
Mori et al., 2016 [12] | NA | VMAT | 39 Gy / 13 fractions | 5 months | NR | Improvement | Partial | None |
Garcia, 2016 [13] | 0.167 | CK | 17 Gy / 1 fraction | 37 months | 8 months | Improvement | Stable | None |
Barrie, 2019 [14] | NA | CK | 25 Gy / 5 fractions | 26 months | 8 (0–65) months | Stable | Progression | None |
Ehret, 2021 [17] | 1.1 | CK | 16 Gy (6–24 Gy) / 1 fraction (1–3) | 8.5 months | 11,7 months | Improvement: 27%, Stable: 30%, Worse: 21% | Complete: 79% patients with follow-up imaging | None |
Our series, 2021 | CK | 30 Gy (25–36 Gy) / 6 fractions (5–6) | 23 months | NR | Improvement: 40%, Stable: 60% | Complete: 25%, Partial: 50%, Stable: 25% | None |